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Abstract.
Background: Recent short-term clinical trials in patients with Duchenne Muscular Dystrophy (DMD) have indicated greater
disease variability in terms of progression than expected. In addition, as average life-expectancy increases, reliable data is
required on clinical progression in the older DMD population.
Objective: To determine the effects of corticosteroids on major clinical outcomes of DMD in a large multinational cohort of
genetically confirmed DMD patients.
Methods: In this cross-sectional study we analysed clinical data from 5345 genetically confirmed DMD patients from 31
countries held within the TREAT-NMD global DMD database. For analysis patients were categorised by corticosteroid
background and further stratified by age.
Results: Loss of ambulation in non-steroid treated patients was 10 years and in corticosteroid treated patients 13 years
old (p = 0.0001). Corticosteroid treated patients were less likely to need scoliosis surgery (p < 0.001) or ventilatory support
(p < 0.001) and there was a mild cardioprotective effect of corticosteroids in the patient population aged 20 years and older
(p = 0.0035). Patients with a single deletion of exon 45 showed an increased survival in contrast to other single exon deletions.
Conclusions: This study provides data on clinical outcomes of DMD across many healthcare settings and including a sizeable
cohort of older patients. Our data confirm the benefits of corticosteroid treatment on ambulation, need for scoliosis surgery,
ventilation and, to a lesser extent, cardiomyopathy. This study underlines the importance of data collection via patient registries
and the critical role of multi-centre collaboration in the rare disease field.
Keywords: Duchenne muscular dystrophy, DMD, Neuromuscular diseases, TREAT-NMD
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LIST OF ABBREVIATIONS
DMD Duchenne Muscular Dystrophy
ENMC European Neuromuscular Centre
GCP Good clinical practice
TGDOC TREAT-NMD Global Database
Oversight Committee
TREAT-NMD Translational Research in Europe –
Assessment & Treatment of
Neuromuscular Diseases.
INTRODUCTION
TREAT-NMD, an “EU funded network of excel-
lence” founded in 2007, has pioneered the formation
of national and global patient registries in the field of
rare neuromuscular diseases. In Duchenne muscular
dystrophy (DMD), TREAT-NMD has facilitated the
establishment of standardised national patient reg-
istries in multiple countries worldwide via the use of
a standardised mandatory data set collected by each
registry [1]. These national registries have combined
data in an effort to create the TREAT-NMD global
database for DMD [2], a unique global resource con-
taining mutational information for over 7000 DMD
patients and clinical data from over 5000 DMD
patients from 31 countries. Data derived from reg-
istries and natural history studies are complementary.
Registries involve much wider population cohorts
and may demonstrate country-specific differences
usually not captured by natural history (observa-
tional) clinical studies. At the same time, natural
history studies provide high quality longitudinal data,
including clinical and multi-disciplinary assessment
not captured by registries. Collectively, they lead
to an increased understanding of the complexity,
variability and progression of DMD [3, 4].
DMD is a progressive, muscle-wasting disease
with an X-linked mode of inheritance, affecting
between 1 in 3500 to 1 in 5000 live male births
globally [5]. Affected boys become symptomatic at
3–5 years of age due to proximal muscle weakness.
Untreated DMD boys lose independent ambulation at
an average age of 9.5 years of age [6]. The use of corti-
costeroids in controlled clinical trials has been shown
to delay this loss of ambulation by 1-2 years [7]. Life-
expectancy is typically limited to the second or third
decade due to respiratory failure or cardiomyopa-
thy. However, the application of ventilatory support
in addition to a multidisciplinary care approach has
lead to a growing adult DMD population, with several
patients surviving as far as the fourth or fifth decades
[8, 9]. Currently there is no cure for DMD. The
implementation of care recommendations (including
corticosteroids, cardiac medications and assisted ven-
tilation) improve outcomes and quality of life, but
their effects on the underlying disease mechanisms
are as yet unknown [10–12]. Many experimental ther-
apies designed to repair the primary genetic defect
are being pursued, including the mutation specific
approach of ‘exon-skipping’ and stop codon read
through therapies (e.g. Altaluren, TranslarnaTM).
However, a lack of comprehensive information on
the natural history of DMD poses significant bar-
riers to applying meaningful outcome measures to
clinical trials, and subsequently to gaining regula-
tory approval. In order to gain a comprehensive
understanding of clinical outcomes and the evolving
heterogeneity of the disease, data from large num-
bers of patients from a variety of countries (where
healthcare often differs) is required. In this study we
determined clinical outcomes in relation to genotype
and corticosteroid treatment in a large, multinational
registry cohort of DMD patients.
MATERIALS AND METHODS
Patients and study design
In this cross-sectional study, we analysed clinical
data from 5345 genetically confirmed DMD (identi-
fication of a pathogenic dystrophin mutation leading
to lack of expression of function dystrophin pro-
tein) patients from 31 countries, held within the
TREAT-NMD global DMD database. Standardised
specific data based on the TREAT-NMD manda-
tory and highly encouraged items were collected
via the national TREAT-NMD patients registries.
Anonymised data from these registries [13] were
transferred to the global DMD-database via a secure
File Transfer Protocol in November 2013 in order to
provide a single anonymised cohort of DMD pheno-
types, clinical data and outcomes.
Patient organisations and patient advocacy groups
were involved and consulted when the study was
designed. Patient groups were represented in the
European Neuromuscular Centre (ENMC) work-
shops, and TREAT-NMD Global Database Oversight
Committee (TGDOC) meetings. In some cases,
national DMD registries are run by patient organ-
isations, so these directly contributed to the data
collection. Patient organisations were also involved
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in publicising information about the registry and
assisting with patient recruitment. The results are dis-
seminated to the patients via registry newsletters and
TREAT-NMD newsletters.
For analysis patients were categorised by corticos-
teroid background (yes, no, past and unknown use)
and then further stratified by age (under the age of 20
and 20 years and older). Age stratification was care-
fully chosen to reduce selection bias in the analysis of
the group of patients under the age of 20 years. Above
the age of 20, study participation declined likely due
to loss to clinical follow-up or death. Analysis of
patients aged 20 years and older should therefore be
interpreted with caution.
Statistical analysis
In the group of patients under the age of 20 years
we used Turnbull estimator to analyse the time to
reach disease milestones (wheelchair dependence,
the need for scoliosis surgery, the need for ventilation
and cardiomyopathy). Turnbull analysis was chosen
because actual event time was not collected (interval-
censored). Turnbull analysis is a generalization of the
Kaplan-Meier estimator and allows the analysis of
interval-censored data [14]. Turnbull estimates were
computed in the software R (www.r-project.org). In
the group of patients aged 20 years and older the
number of deceased patients was considered signifi-
cantly and increasing with time, but an exact number
was not known. Therefore Turnbull or Kaplan Meier
estimator could not be used. Instead we used chi-
square analysis to analyse the effect of corticosteroids
on disease milestones above the age of 20 years. Chi-
square analysis was carried out in Graph pad Prism
(GraphPad Software, La Jolla, CA 92037 USA).
RESULTS
Patients
The global TREAT-NMD DMD registry contains
7149 DMD patients. For one quarter of the records
(25.2%: n = 1804) incomplete clinical information
was provided, leaving 5345 patients suitable for
in-depth clinical analysis. 84.4% (n = 4509) of the
patients were under the age of 20 years and 15.6%
(n = 836) were 20 years and older. (Table S1. in the
Supplementary Appendix shows an overview of the
number of patients in the database per age group
and the number of patients analysed per clinical
milestone).
Country specific differences in patient popu-
lations were observed in the dataset. Generally,
long-standing registries (in existence for more than
5 years) had higher numbers of older patients than
newer registries. The oldest patient populations in
the database come from Japan and the Netherlands,
with as high as 7% of their registry population being
older than age 30.
Corticosteroid use
Corticosteroid use within the registry was recorded
in four main categories: “corticosteroids yes” (reflect-
ing current corticosteroid use, dose unspecified),
“corticosteroids no” (reflecting never used cor-
ticosteroids) and “past corticosteroid use”(dose,
duration of past use and stopping reasons not spec-
ified). Almost half of the study population (49.7%:
n = 2658) were currently using steroids, 37.7%
(n = 2015) had never used corticosteroids and 9.8%
(n = 522) reported past steroids used. For the remain-
ing 2.8% (n = 150) patients the use of corticosteroids
was unknown. Corticosteroid use varied with age;
younger patients reported more corticosteroid use
than older patients. Current care standards recom-
mend commencing corticosteroid use at around 4–6
years of age [15]; and this was reflected within the
database. Until the age of 14 years corticosteroid
use within the database increased in an age depen-
dent manner, with patients aged 6–8, 9–11 and 12–14
reporting the greatest corticosteroid use (57%, 74%
and 64% respectively) (Fig. 1). Corticosteroid use
notably decreased after the age of 14 as ambulation
decreased. In the database, population 20 years and
older, only 15.2% (n = 127) of patients reported cur-
rent corticosteroid use. This was further reduced in
the population aged 30 years and older where only
4.4% (n = 6 of 135) reported current corticosteroid
use. The early use of corticosteroids has only been
common practice since 2004, and DMD patients born
before 1998 are less likely to have ever used cor-
ticosteroids. (Table S2. in the supplementary index
provides an overview of corticosteroid use per age
group within the database).
Corticosteroids and clinical milestones in
patients under the age of 20 years
Ambulation
The proportion of ambulant and non-ambulant
patients correlated with age and also independently
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Fig. 1. Overview of corticosteroid use within the global TREAT-NMD DMD database. Corticosteroid was reported as “corticosteroids yes”
(current corticosteroid users/red bars), “corticosteroids never used ”(corticosteroids never used/green bars), “past corticosteroid use” (used
corticosteroids in the past/blue bars) or “corticosteroid use unknown” (corticosteroid use unknown/orange bars”).
with the use of corticosteroids. In the non-steroid
treated population, 71% (n = 633) of patients under
the age of 10 years remained ambulant (Fig. 2 and the
corresponding Table S3. in the supplementary index).
Beyond this age range, ambulation decreased signif-
icantly, with 52% (n = 464) of the non-steroid treated
patients remaining ambulant at the age of 10 years.
By comparison 79% (n = 1375) of patients currently
taking steroids, remained ambulant at the age of 10
years. Median age at loss of ambulation in non-steroid
treated patients was 10 years old, compared with 13
years in the steroid treated patients (p < 0.001).
Scoliosis surgery
A total of 9% (n = 488) of the registry patients
have had scoliosis surgery. Forty two percent
(n = 205) of these patients were under the age of
20 years. Turnbull analysis showed that from the
age where patients begin to require scoliosis surgery
(14 years and onwards), the use of corticosteroids
significantly reduced the number of patients having
scoliosis surgery (p < 0.001) (Figure S1A. in the
Supplementary Appendix).
Ventilation
Overall 10.3% (n = 549) of registry patients used
assisted ventilation. Assisted ventilation fell into
two categories, non-invasive (nasal/mouth mask)
or invasive (tracheostomy). Non-invasive ventila-
tion accounted for 74.0% (n = 406) of the ventilated
population (average age 25.5 years) and invasive
ventilation for 25.0% (n = 137) (average age 28.1
years). For 1.1% (n = 6) of the patients type of venti-
lation was unknown. The use of assisted ventilation
increased with age (Fig. 3) with 2.9% (n = 129) of the
patients under the age of 20 years reporting the use of
assisted ventilation, compared with 50.4% (n = 420)
of patients aged 20 years and older. As shown by
Turnbull analysis corticosteroids had a positive effect
on ventilation (p < 0.001) (Figure S1B. in the Supple-
mentary Appendix).
Cardiomyopathy
Cardiomyopathy was reported in 12.0% (n = 639)
of registry patients. In 66.5% (n = 425) diagno-
sis was based on a reduced ejection fraction on
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Fig. 2. Turnbull analysis for loss of ambulation. The red line
indicates the “corticosteroid yes” group, the green line the
“corticosteroid no (never)” group and the blue line the “past corti-
costeroid use” group. P-value indicates the difference between the
steroid: yes and steroid: no groups.
Fig. 3. Assisted ventilation within the global TREAT-NMD DMD
database.
echocardiogram. In the remaining 34.5% (n = 214)
the diagnostic methods were not available. Preva-
lence of cardiomyopathy in the database increased
with age with 6.7% (n = 302) of patients aged 20
and under reporting cardiomyopathy and 40.4%
(n = 337) of patients aged 20 and above having car-
diomyopathy. Until the age of 20 no significant
effect of corticosteroids on the development of car-
diomyopathy was observed (p = 0.94). Importantly,
no trend for a negative effect of the use of corticos-
teroids was seen (Figure S1C. in the Supplementary
Appendix).
Corticosteroids and clinical milestones in
patients aged 20 years and older
Whilst the majority of patients in the DMD global
database were less than 20 years old, there was a
sizable cohort of patients aged 20 and over 15.6%
(n = 836).
33.9% (n = 283) of patients aged 20 years and
older underwent scoliosis surgery. As observed in
the younger patients group, the frequency of scol-
iosis surgery was lower in the corticosteroid treated
population (χ2 4.4 p < 0.0001) (Fig. 4A). Assisted
ventilation was reported in 50.4% (n = 420) of
patients over the age of 20 years. 4.8% (n = 20) of
these patients reported using corticosteroids, 16.9%
(n = 70) reported past use, 75.5% (n = 318) reported
never having used corticosteroids, and for 2.6%
(n = 11) corticosteroid use was unknown. Chi-square
testing of this group showed that corticosteroid use
is associated with significantly less use of assisted
ventilation (χ2 7.2 p < 0.0001) (Fig. 4B). Gener-
ally, non-invasive ventilation was utilised more than
invasive ventilation except for patients over the
age of 35. Patients aged 30 or older (n = 152)
showed 75.5% (n = 115) dependence on assisted ven-
tilation (36.5%: n = 42 invasive, 50%: n = 76 non-
invasive).
In contrast to the younger age group, further anal-
ysis of patients aged 20 years and older showed a
cardioprotective effect of corticosteroids. Chi-square
testing showed that in this age group cardiomyopa-
thy was less frequent in the cohort using steroids
(42%: n = 31) than in the past treated (62%: n = 71) or
never steroid treated (60%:n = 229) cohorts (χ2 2.9,
p = 0.0035) (Fig. 4C).
Genotype analysis in older age groups
We examined different age ranges of the older
cohort of patients for most frequent mutations to
assess whether any mutations in particular predis-
pose to more severe or less severe course of disease.
Whilst distribution of mutation type within the pop-
ulation aged 20 years and older was similar to the
genotype distribution in the patient group under the
age of 20 years (with deletions being most frequent
followed by small rearrangements then duplications),
detailed analysis showed that deletion of exon 45
was the most frequent mutation in the cohort aged
20 years and older accounting for 6.7% (n = 56) of
the population. In contrast, this mutation was present
in only 4.3% (n = 196) of patients under the age of
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Fig. 4. Chi-square testing for scoliosis surgery (A), ventilation (B) and cardiomyopathy (C) in the patient group aged 20 years and older.
20 years. (Fig. S2A. and B. in the Supplementary
Appendix). In addition, patients under the age of 20
years, never treated with corticosteroids and with a
single exon deletion of exon 45 lost ambulation sig-
nificantly later (mean age 15 years old) than patients
in this age group with other most common single exon
deletions (deletion exon 51, 44, 52 and 50) (mean
age 11 years) (p = 0.027) (Fig. 5A). When treated
with corticosteroids no significant difference in loss
of ambulation was observed (p = 0.52) (Fig. 5B). The
data was then further stratified to compare the above-
mentioned group of patients with single exon deletion
45 with mutations that would be rescued by cur-
rent exon skipping strategies, specifically “skip exon
44” (excluding single exon deletion 45) and “skip
exon 51” (excluding single exon deletion 50). An
advantage was observed in terms of loss of ambu-
lation for both single exon deletion 45 and the skip
exon 44 group (Fig. 6A), but not for deletions includ-
ing exon 45 that cannot be brought back into frame
by exon 44 skipping. In the corticosteroid treated
population median age of loss of ambulation for
single exon deletion 45, skip exon 44, as well as
the single exon deletion 50 and the skip exon 51,
were in the same median age range (14 to15 years),
(Fig. 6B).
DISCUSSION
DMD is a severe, progressive condition affecting
1 in 3600–6000 live male births [15–16]. A range of
therapeutic approaches targeted at causative muta-
tions of the dystrophin gene have been proposed
including exon-skipping, which aims to restore the
correct reading frame and result in expression of at
least partly functional dystrophin protein [17–21],
and techniques to enable readthrough of premature
stop codons. Despite promising results in early stage
studies, failure of recent phase 3 trials to meet pri-
mary endpoints [22] suggests the clinical variability
of DMD is greater than anticipated and that this may
mask treatment benefit. Variability may partly be due
to the disease-modifying effect of long-term corticos-
teroid use, increasingly common amongst younger
patients, as recommended in international consensus
guidelines [15, 16, 23]. Data from smaller natural
history studies and national registries has also sug-
gested that changes in care and particular mutations
in the dystrophin gene may be correlated with clinical
outcomes [24, 25].
The current evidence for corticosteroid treatment
in DMD is largely from short-term data from ran-
domised control trials; long-term data, particularly
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Fig. 5. Turnbull analysis of loss of ambulation in patients under the age of 20 years, never (A) and ever (B) treated with corticosteroids and
with a single exon deletion of exon 45 (red line), exon 51 (green line), exon 44 (purple line), exon 52 (black line) and exon 50 (blue line).
Fig. 6. Turnbull analysis of loss of ambulation in patients under the age of 20 years in mutations rescued by exon skip 44 and 51. (A)
represents patients never treated with corticosteroids and (B) represents patients ever treated with corticosteroids. In both figures the red line
indicates patients with deletion of exon 45 mutation, the green line indicates patients with mutations amenable to exon skipping with exon
44 (but not deletion of exon 45 mutations), the blue line indicates patients with deletion of exon 50 mutation and the black line indicates
patients with mutations amenable to exon skipping with exon 51 (but not deletion of exon 50 mutations).
on prolongation of ambulation, are limited [26]. Our
study shows that corticosteroids are advantageous
for all major clinical outcomes. Patients taking cor-
ticosteroids retain ambulation status for longer, have
scoliosis surgery less frequently, require ventilatory
support later in life, and have a lower incidence of
cardiomyopathy (in patients ≥20 years). While the
mechanism underlying this advantage is still not com-
pletely understood, it is thought that corticosteroids
may act to reduce the rate of muscle breakdown
[27], and may reduce muscle necrosis and inflam-
mation [28]. However, not all immunosuppressive
or anti-inflammatory drugs have an effect on DMD,
suggesting immunosuppression is not the only func-
tion of corticosteroids [29]. Alternative possible
mechanisms of action are through increasing the
number of muscle precursor cells [30, 31].
While advantages of corticosteroids are clear
in terms of ambulation, their impact on skeletal
defects, ventilation or cardiomyopathy has been
controversial so far. Retrospective studies in Japanese
DMD patients using the Remudy patient registry have
shown patients using prednisolone lose ambulation
on average 11 months later than their non-steroid
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treated counterparts [32]. Our results confirm the
profound effect of corticosteroid treatment on ambu-
lation, scoliosis surgery, ventilatory support and, to
a lesser extent, cardiomyopathy [33]. Patients not
treated with corticosteroids have a 90% probability
of developing a clinically significant progressive sco-
liosis [34]. Daily corticosteroid use has been shown
to reduce the incidence of scoliosis [35, 36]. Our data
show that patients currently taking corticosteroids are
less likely to have had scoliosis surgery. Furthermore,
our data show that patients currently taking corticos-
teroids are less likely to require ventilatory support.
There have been previous concerns that, due to pre-
served skeletal muscle function and thus increased
stress on a vulnerable myocardium, corticosteroids
may worsen cardiomyopathy in DMD [37]. In our
cohort, no negative effects of the use of corticos-
teroids on the heart were observed. Moreover, in the
cohort of patients aged ≥20 years a cardioprotective
effect was observed.
Corticosteroids tend to be initially prescribed in
patients around age 4–6 years and discontinued at or
shortly after permanent wheelchair dependence. We
acknowledge this as a limitation of our study analysis
since some patients will have stopped taking corticos-
teroids once they have permanently lost ambulation
and were therefore considered “past steroid users” in
our study. In this group, patients with unfavourable
genotypes, lack of response to corticosteroids or
intolerable side effects may be overrepresented. In
general, our analysis in the older DMD population
may be biased towards favourable outcomes, as –
based on voluntary registration of living individu-
als – deceased patients are not included. This may
be reflected in a lower than expected percentage of
scoliosis surgery, cardiomyopathy and ventilation in
patients aged ≥20 years.
Historically the clinical progression of DMD was
considered relatively homogeneous with predictable
outcomes for muscle function and survival. We show
that there is greater variability in clinical progres-
sion and outcomes than previously reported, with
increasing evidence for the role of genetic modifiers
[24, 38, 39]. Our analysis revealed that specific exons
were associated with either positive or negative effects
on disease severity. Such mutation specific responses
have been suggested in case reports and smaller clin-
ical studies [25, 40]. Our data highlights that single
deletions of exon 45 may infer and advantage to sur-
vival when compared to other common single exon
deletions. This could be due to exon 45 deletions
having a higher frequency of spontaneous exon 44
skipping, giving rise to small amounts of functional
dystrophin protein and resulting in long-term clinical
benefit, as suggested by data from a smaller cohort
[41]. This supports the use of exon-skipping anti-
sense oligonucleotides to restore the reading frame of
dystrophin mRNA and the further exploration of its
potential therapeutic applications in DMD [17–21].
The global DMD platform continues its devel-
opment by recruiting new members and national
registries under the TREAT-NMD framework. Active
research in the treatment of DMD introduces the
need for post-marketing surveillance in the long-
term assessment of safety and efficacy of therapeutic
approaches. The global DMD registry is a good
starting point in disease specific long-term data col-
lection, which will allow the collection of specific
post-marketing data and comparison of different
therapeutic approaches. This work requires multicen-
tre, multinational collaboration, an agreed additional
standardized data set (e.g. adverse events forms)
and agreed user roles (e.g. patient reported/clinician
reported data) inbuilt in national registries to allow
comprehensive, Good Clinical Practice (GCP) com-
pliant data collection. Data collected in this way can
contribute to better understanding of the course of the
disease, disease management, and safety and efficacy
profile of new therapies, and ultimately may lead to
new policies and disease management protocols.
The infrastructure provided by TREAT-NMD and
the standardized, common data set collected by the
TREAT-NMD national registries has ultimately facil-
itated the formation of the TREAT-NMD global
database for DMD [2]. This is a collection of
more than 7000 genetically confirmed DMD patients
worldwide of which we have clinical data, which
passed quality control for 5345 patients. To our
knowledge this is the single largest cohort of genet-
ically confirmed DMD patients to date and has
allowed us to highlight important DMD clinical mile-
stones and outcomes. To facilitate the inclusion of
patients, a flexible reporting methodology has been
applied that makes use of both patient self-report
and professional report depending on differences in
medical and cultural conditions as well as practi-
cal considerations such as cost effectiveness. Great
care has been taken in training, standardization, and
curation, but some variability in reporting between
different sites and countries is inherent to the reg-
istry approach. The trends uncovered will need to be
taken into consideration for novel DMD treatments
like exon-skipping, but will also have impact on DMD
prognosis, management and care standards.
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In addition to allowing access to large amounts
of data, registries provide a mechanism for col-
lecting longitudinal data at relatively low cost and
often include information on patients who would be
excluded from natural history studies or clinical trials.
Unlike in randomized clinical trials, causality can-
not be firmly established from registry data and we
accept this as a limitation of our study. However, our
data may help to power future clinical trials by high-
lighting the need for trial design to take into account
the heterogeneity of the DMD population including
patient age, mutation type and corticosteroid back-
ground. The data collected via registries contribute to
better understanding of the cost-effectiveness of new
therapies, allows assessment of the burden of illness,
and helps in planning health economic actions and
model healthcare system for a specific rare condition
in the most effective way. It is also very reassuring
that the association of corticosteroid treatment with
improved clinical outcomes can be observed in the
“real world” across many different countries with dif-
ferent healthcare settings and ethnic backgrounds and
regardless of a specific corticosteroid regime.
CONCLUSIONS
Clinical trials in rare disorders such as DMD are
challenging, expensive and liable to low recruitment
numbers, lack of validation of outcomes in larger
cohorts, and variability of assessment across multi-
ple centres or countries. Power calculations are often
based on assumptions and on data on a limited num-
ber of participants in single centres, and recent trials
to prove the efficacy of novel drugs in DMD have
not reached their primary endpoint in measures like
the 6-minute-walk test [22]. While well-controlled
clinical studies including natural history studies are
expected to improve this knowledge and to de-risk
future trials, complementary and supporting infor-
mation can be obtained from pooling a limited, but
well standardized set of data across multiple registries
and countries. This cross-sectional approach allows
correcting for country- or site-specific differences
and for long-term changes in “real-world” standards
of care and treatment. We suggest that through this
approach, better assumptions of the variability in out-
comes can be obtained, and power calculations and
stratification strategies improved. In addition, with
the development of new genetic therapies, comes
the need for post-marketing surveillance to assess
the long-term safety and efficacy of novel therapies.
The global DMD registry will serve as an important
initial source this information, allowing the genera-
tion of disease specific long-term data and facilitating
the comparison of different therapeutic approaches,
using standardized methods of data collection.
DECLARATIONS
Ethics approval and consent to participate
Ethics approval was obtained by national registries
from local REC committees. Patients consented for
participation and by national registries in accordance
with national standards.
Consent for publication
Participants gave informed consent for data
sharing.
Availability of data and material
The datasets used and analysed during the current
study are available from the corresponding author on
reasonable request.
Conflict of interest
All authors declare: no support from any organisa-
tion for the submitted work; no financial relationships
with any organisations that might have an interest in
the submitted work in the previous three years; no
other relationships or activities that could appear to
have influenced the submitted work. Professor Hanns
Lochmu¨ller was elected chair of the TREAT-NMD
Alliance in April 2012. He and Jan Verschuuren both
served as chairs of the oversight committee.
Funding
This work was supported by TREAT-NMD operat-
ing grants, FP6 LSHM-CT-2006-036825, 20123307
UNEW FY2013 and AFM 16104. Further support
came from the European Union Seventh Frame-
work Programme (FP7/2007-2013) under grant
agreement No. 305444 (RD-Connect) and 305121
(Neuromics) and Medical Research Council UK (ref-
erence G1002274, grant ID 98482). Original data
collection was facilitated by national registries, which
have received public and patient organisation fund-
ing. No private company funding was received for
any aspect of this work.
Z. Koeks et al. / Clinical Outcomes in Duchenne Muscular Dystrophy 303
AUTHORS’ CONTRIBUTIONS
Initials Name Role Contribution
CLB Catherine L Bladen Senior Process Development Scientist Was a major contributor in writing the manuscript.
Performed data analysis and interpretation
ZK Zaı¨da Koeks 3rd year PhD student and neurologist in
training
Was a major contributor in writing the manuscript.
Performed data analysis and interpretation
DS David Salgado Research Engineer Analysed and interpreted the patient data
EvZ Erik van Zwet Associate Professor Analysed and interpreted the patient data
OP Oksana Pogoryelova Senior Research Associate Analysed and interpreted the patient data,
contributed to manuscript writing
GM Grace McMacken Clinical Research Associate Analysed and interpreted the patient data,
contributed to manuscript writing
SM Soledad Monges Neurologist Analysed and interpreted the patient data,
Contributed to data acquisition
MEF Maria E Foncuberta Genetic Epidemiology, Pediatrics,
Otolaryngology
Analysed and interpreted the patient data,
Contributed to data acquisition
KK Kuriaki Kekou Biologist PhD Analysed and interpreted the patient data,
Contributed to data acquisition, Contributed to
data acquisition
KK Konstantina Kosma Paediatrician Analysed and interpreted the patient data,
Contributed to data acquisition
HD Hugh Dawkins Director, Office of Population Health
Genomics
Analysed and interpreted the patient data,
Contributed to the study design and concept
LL Leanne Lamont Office of Population Health Genomics Analysed and interpreted the patient data,
Contributed to data acquisition
MIB Matthew I Bellgard Director, Centre for Comparative Genomics
(CCG)
Analysed and interpreted the patient data,
Contributed to data acquisition
AJR Anna J Roy Research Scientist Analysed and interpreted the patient data,
Contributed to data acquisition
TC Teodora Chamova Medical doctor at Clinic of neurology Analysed and interpreted the patient data,
Contributed to data acquisition
VG Velina Guergueltcheva Child neurologist at EduSeeker Analysed and interpreted the patient data,
Contributed to data acquisition
SC Sophelia Chan Associate Consultant Analysed and interpreted the patient data,
Contributed to data acquisition
LK Lawrence Korngut Director, Calgary ALS and Motor Neuron
Disease Clinic; Neurologist, Calgary
Neuromuscular Clinic
Analysed and interpreted the patient data,
Contributed to data acquisition
CC Craig Campbell Paediatric Neurology Analysed and interpreted the patient data,
Contributed to data acquisition
YD Yi Dai Gynaecology Analysed and interpreted the patient data,
Contributed to data acquisition
JW Jen Wang Joint founder of the China DMD Care and
Support Association
Analysed and interpreted the patient data,
Contributed to data acquisition
NB Nina Barisˇic´ Paediatrician Analysed and interpreted the patient data,
Contributed to data acquisition
PB Petr Brabec Vice-director for quality and management Analysed and interpreted the patient data,
Contributed to data acquisition
JL Jaana Lahdetie Senior Consultant in Child Neurology Analysed and interpreted the patient data,
Contributed to data acquisition
MCW Maggie C Walter Neurologist Analysed and interpreted the patient data,
Contributed to data acquisition
OLK Olivia Schreiber-Katz Neurologist Analysed and interpreted the patient data,
Contributed to data acquisition
VK Veronika Karcagi Head of Department of Molecular Genetics
and Diagnostics
Analysed and interpreted the patient data,
Contributed to data acquisition
MG Marta Garami TREAT-NMD database manager for
Eastern-European Countries
Analysed and interpreted the patient data,
Contributed to data acquisition
AH Agnes Herczegfalvi Leader of Neuromuscular Diseases Centre Analysed and interpreted the patient data,
Contributed to data acquisition
VV Venkatarman
Viswanathan
Faculty Associate Analysed and interpreted the patient data,
Contributed to data acquisition
(Continued)
304 Z. Koeks et al. / Clinical Outcomes in Duchenne Muscular Dystrophy
AUTHORS’ CONTRIBUTIONS (Continued)
Initials Name Role Contribution
FB Farhad Bayat Head of Laboratory at the Pasteur Institute of
Iran
Analysed and interpreted the patient data,
Contributed to data acquisition
FB Filippo Buccellla Italian DMD Registry Curator Analysed and interpreted the patient data,
Contributed to data acquisition
AF Alessandra Ferlini Associate Professor in Medical Genetics,
Director of the section of Medical Genetics
Analysed and interpreted the patient data,
Contributed to data acquisition
EK En Kimura Chief of Early Stage Exploratory Clinical
Trial Unit
Analysed and interpreted the patient data,
Contributed to data acquisition
JCvdB Janneke C van den Bergen MD – Neurology Analysed and interpreted the patient data,
Contributed to data acquisition
MR Miriam Rodrigues New Zealand NMD Registry Curator Analysed and interpreted the patient data,
Contributed to data acquisition
RR Richard Roxburgh Neurologist Analysed and interpreted the patient data,
Contributed to data acquisition
AL Anna Lusakowska Clinical expert; Principal investigator of
clinical trial
Analysed and interpreted the patient data,
Contributed to data acquisition
AKP Anna Kostera-Pruszczyk Clinical expert, Neurologist Analysed and interpreted the patient data,
Contributed to data acquisition
RS Rosa´rio Santos Manager of registry; Director of laboratory Analysed and interpreted the patient data,
Contributed to data acquisition
EN Elena Neagu Paediatric Neurologist Analysed and interpreted the patient data,
Contributed to data acquisition
SA Svetlana Artemieva Paediatric Neurologist Analysed and interpreted the patient data,
Contributed to data acquisition
VMR Vedrana Milic Rasic Curator of DMD and SMA Registry in
Serbia
Analysed and interpreted the patient data,
Contributed to data acquisition
DV Dina Vojinovic PhD candidate at Erasmus MC Analysed and interpreted the patient data,
Contributed to data acquisition
MP Manuel Posada Director, Institute of Rare Diseases Research Analysed and interpreted the patient data,
Contributed to data acquisition
CB Clemens Bloetzer Clinical expert Analysed and interpreted the patient data,
Contributed to data acquisition
AK Andrea Klein Dr; Contact person of registry Analysed and interpreted the patient data,
Contributed to data acquisition
JDM Jordi Dı´az-Manera Clinical expert; Investigator of research
project
Analysed and interpreted the patient data,
Contributed to data acquisition
EG Eduard Gallardo Biologist; Senior Researcher Analysed and interpreted the patient data,
Contributed to data acquisition
AAK A. Ays¸e Karaduman Turkish DMD and SMA Registry Curator
(Ankara)
Analysed and interpreted the patient data,
Contributed to data acquisition
TOY Tunca Oznur Yilmaz Professor of Neonatal and Paediatrics
Hereditary Muscle Disorders
Analysed and interpreted the patient data,
Contributed to data acquisition
HT Haluk Topalog˘lu Professor of Paediatrics and Neurology Analysed and interpreted the patient data,
Contributed to data acquisition
EeS Rasha El Sherif Consultant of Neurology and Head of
Neurogenetics Unit – Air Hospital, Egypt
Analysed and interpreted the patient data,
Contributed to data acquisition
AS Angela Stringer DMD Registry Curator Analysed and interpreted the patient data,
Contributed to data acquisition
AVS Andriy V Shatillo Neurologist, DMD registry curator Analysed and interpreted the patient data,
Contributed to data acquisition
ASM Ann S Martin Genetic Counselor & DuchenneConnect
Coordinator
Analysed and interpreted the patient data,
Contributed to data acquisition
HLP Holly L Peay Assistant Professor Analysed and interpreted the patient data,
Contributed to data acquisition
JK Jan Kirschner Consultant Pediatric Neurologist, Deputy
Head of Division
Contributed to the study design and concept
KMF Kevin M Flanigan Attending Neurologist Contributed to the study design and concept
VS Volker Straub Harold Macmillan Professor of Medicine Contributed to the study design and concept
KB Kate Bushby Act. Res.Chair of Neuromuscular Genetics Contributed to the study design and concept
(Continued)
Z. Koeks et al. / Clinical Outcomes in Duchenne Muscular Dystrophy 305
AUTHORS’ CONTRIBUTIONS (Continued)
Initials Name Role Contribution
CB Christophe Be´roud Assistant Professor of Genetics, head of the
bioinformatics team at the UMR S 910
research unit
Contributed to the study design and concept
JV Jan Verschuuren Head of Neuromuscular Section,
Department of Neurology
Contributed to the study design and concept
HL Hanns Lochmu¨ller Professor of Experimental Myology Contributed to the study design and concept
All authors read and approved the final manuscript.
ACKNOWLEDGMENTS
This work was supported by TREAT-NMD operat-
ing grants, FP6 LSHM-CT-2006-036825, 20123307
UNEW FY2013 and AFM 16104. Further support
came from the European Union Seventh Frame-
work Programme (FP7/2007-2013) under grant
agreement No. 305444 (RD-Connect) and 305121
(Neuromics) and Medical Research Council UK (ref-
erence G1002274, grant ID 98482).
The authors would like to acknowledge the
families of those living with Duchenne muscular dys-
trophy who have been instrumental in the formation
of the DMD national registries. We also acknowledge
former and current members of the TREAT-NMD
office at the Institute of Genetic Medicine in New-
castle including Stephen Lynn, Emma Heslop and
Rachel Thompson. We also extend our thanks to
the members of the TREAT-NMD executive com-
mittee: Hanns Lochmu¨ller, Annemieke Aartsma-Rus,
Anna Ambrosini, Filippo Buccella, Kevin Flanigan,
Eric Hoffman, Janbernd Kirschner, Eugenio Mer-
curi, Ichizo Nishino, Kathy North, Jes Rahbek and
Thomas Sejersen. We also acknowledge the members
of the current TGDOC: Nathalie Goemans (Chair),
Craig Campbell (Vice Chair), Hugh Dawkins (Out-
going Chair), Anna Ambrosini, Svetlana Artemieva,
Alexander N. Baranov, Farhad Bayat, Christophe
Be´roud, Ria Broekgaarden, Filippo Buccella, Craig
Campbell, Nick Catlin (former TGDOC member),
Monica Ensini, Pat Furlong, Kevin Flanigan, Ole
Gredal, Lauren P. Morgenroth, Serap ˙Inal, Jacqueline
Jackson, Pierre-Yves Jeannet, Anna Kaminska, A.
Ayse Karaduman, Veronika Karcagi, En Kimura, Jan-
bernd Kirschner, Jaana La¨hdetie, Hanns Lochmu¨ller,
Vitaliy Matyushenko, Vedrana Milic Rasic, Violeta
Mihaylova, Marie-Christine Ouillade, Ian Murphy,
Miriam Rodrigues, Rosario dos Santos, Pascale
Saugier-Veber, Inge Schwersenz, Thomas Sejersen,
Rasha El Sherif, Eduardo Tizzano, Isabela Tudo-
rache, Sylvie Tuffery-Giraud, Jen Wang, Simon
Woods, W. Ludo van der Pol, Peter Van den Bergh,
Petr Vondra´cˇek, Jan Verschuuren.
SUPPLEMENTARY MATERIAL
The supplementary material is available in the
electronic version of this article: http://dx.doi.
org/10.3233/JND-170280.
REFERENCES
[1] Bladen CL, Rafferty K, Straub V, Monges S, Moresco A,
Dawkins H, et al. The TREAT-NMD duchenne muscular
dystrophy registries: Conception, design, and utilization
by industry and academia. Human Mutation. 2013;34(11):
1449-57.
[2] Bladen CL, Salgado D, Monges S, Foncuberta ME, Kekou
K, Kosma K, et al. The TREAT-NMD DMD global database:
Analysis of more than 7,000 duchenne muscular dystrophy
mutations. Human Mutation. 2015;36(4):395-402.
[3] Pane M, Mazzone ES, Sivo S, Sormani MP, Messina S,
D′Amico A, et al. Long term natural history data in ambu-
lant boys with duchenne muscular dystrophy: 36-month
changes. PLoS One. 2014;9(10):e108205.
[4] Henricson EK, Abresch RT, Cnaan A, Hu F, Duong T, Arri-
eta A, et al. The cooperative international neuromuscular
research group Duchenne natural history study: Glucocorti-
coid treatment preserves clinically meaningful functional
milestones and reduces rate of disease progression as
measured by manual muscle testing and other commonly
used clinical trial outcome measures. Muscle & Nerve.
2013;48(1):55-67.
[5] Mendell JR, Shilling C, Leslie ND, Flanigan KM, al-Dahhak
R, Gastier-Foster J, et al. Evidence-based path to newborn
screening for Duchenne muscular dystrophy. Ann Neurol.
2012;71(3):304-13.
[6] Gowers WR, Taylor J. A manual of diseases of the nervous
system. London: J. & A. Chuchill; 1892.
[7] Humbertclaude V, Hamroun D, Bezzou K, Be´rard C,
Boespflug-Tanguy O, Bommelaer C, et al. Motor and res-
piratory heterogeneity in Duchenne patients: Implication
forclinical trials. European Journal of Paediatric Neurology.
2012;16(2):149-60.
[8] Baxter P. Treatment of the heart in Duchenne muscular
dystrophy. Developmental Medicine & Child Neurology.
2006;48(03):163.
[9] Emery AEH. The muscular dystrophies. The Lancet.
2002;359(9307):687-95.
[10] Hoffman EP, Reeves E, Damsker J, Nagaraju K, McCall
JM, Connor EM, et al. Novel Approaches to Corticosteroid
Treatment in Duchenne Muscular Dystrophy. Physical
Medicine and Rehabilitation Clinics of North America.
2012;23(4):821-8.
[11] Sejerson T, Bushby K. Standards of Care for Duchenne
Muscular Dystrophy: Brief Treat-NMD Recommendations.
306 Z. Koeks et al. / Clinical Outcomes in Duchenne Muscular Dystrophy
In: Espino´s C, Felipo V, Palau F, editors. Inherited
Neuromuscular Diseases: Springer Netherlands; 2009.
pp. 13-21.
[12] Landfeldt E, Lindgren P, Bell CF, Schmitt C, Guglieri M,
Straub V, et al. Compliance to care guidelines for duchenne
muscular dystrophy. Journal of Neuromuscular Diseases.
2015;2(1):63-72.
[13] Bladen CL, Rafferty K, Straub V, Monges S, Moresco A,
Dawkins H, et al. The TREAT-NMD Duchenne muscular
dystrophy registries: Conception, design, and utilization by
industry and academia. Hum Mutat. 2013;34(11):1449-57.
[14] Turnbull BW. The empirical distribution function with arbi-
trarily grouped, censored and truncated data. Journal of
the Royal Statistical Society. Series B (Methodological).
1976:290-95.
[15] Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR,
Cripe L, et al. Diagnosis and management of Duchenne
muscular dystrophy, part 1: Diagnosis, and pharmacolog-
ical and psychosocial management. The Lancet Neurology.
2010;9(1):77-93.
[16] Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR,
Cripe L, et al. Diagnosis and management of Duchenne mus-
cular dystrophy, part 2: Implementation of multidisciplinary
care. The Lancet Neurology. 2010;9(2):177-89.
[17] Aartsma-Rus A, Fokkema I, Verschuuren J, Ginjaar I, van
Deutekom J, van Ommen G-J, et al. Theoretic applicability
of antisense-mediated exon skipping for Duchenne mus-
cular dystrophy mutations. Human Mutation. 2009;30(3):
293-9.
[18] Aartsma-Rus A, Janson AAM, Kaman WE, Bremmer-Bout
M, den Dunnen JT, Baas F, et al. Therapeutic antisense-
induced exon skipping in cultured muscle cells from
six different DMD patients. Human Molecular Genetics.
2003;12(8):907-14.
[19] Aartsma-Rus A, Janson AAM, Kaman WE, Bremmer-
Bout M, van Ommen G-JB, den Dunnen JT, et al.
Antisense-induced multiexon skipping for duchenne mus-
cular dystrophy makes more sense. The American Journal
of Human Genetics. 2004;74(1):83-92.
[20] van Ommen G-J, van Deutekom J, Aartsma-Rus A. The
therapeutic potential of antisense-mediated exon skipping.
Curr Opin Mol Ther. 2008;10(2):140-9.
[21] van Ommen G-JB, Aartsma-Rus A. Advances in therapeutic
RNA-targeting. New Biotechnology. 2013;30(3):299-301.
[22] Bushby K, Finkel R, Wong B, Barohn R, Campbell C,
Comi GP, et al. Ataluren treatment of patients with nonsense
mutation dystrophinopathy. Muscle & Nerve. 2014;50(4):
477-87.
[23] Gloss D, Moxley RT 3rd, Ashwal S, Oskoui M. Prac-
tice guideline update summary: Corticosteroid treatment
of Duchenne muscular dystrophy: Report of the Guideline
Development Subcommittee of the American Academy of
Neurology. Neurology. 2016;86(5):465-72.
[24] Bello L, Piva L, Barp A, Taglia A, Picillo E, Vasco G, et
al. Importance of SPP1 genotype as a covariate in clin-
ical trials in Duchenne muscular dystrophy. Neurology.
2012;79(2):159-62.
[25] van den Bergen JC, Ginjaar HB, Niks EH, Aartsma-Rus
A, Verschuuren JJGM. Prolonged ambulation in duchenne
patients with a mutation amenable to exon 44 skipping.
Journal of Neuromuscular Diseases. 2014;1(1):91-4.
[26] Matthews E, Brassington R, Kuntzer T, Jichi F, Manzur
AY. Corticosteroids for the treatment of Duchenne
muscular dystrophy. Cochrane Database Syst Rev. 2016;(5):
CD003725.
[27] Rifai Z, Welle S, Moxley RT, Lorenson M, Griggs RC. Effect
of prednisone on protein metabolism in Duchenne dystro-
phy. American Journal of Physiology - Endocrinology and
Metabolism. 1995;268(1):E67-E74.
[28] Spuler S, Engel AG. Unexpected sarcolemmal complement
membrane attack complex deposits on nonnecrotic muscle
fibers in muscular dystrophies. Neurology. 1998;50(1):41-6.
[29] Griggs RC, Moxley RT 3rd, Mendell JR, Fenichel GM,
Brooke MH, Pestronk A, et al. Duchenne dystrophy: Ran-
domized, controlled trial of prednisone (18 months) and
azathioprine (12 months). Neurology. 1993;43(3 Pt 1):
520-7.
[30] Pasquini F, Guerin C, Blake D, Davies K, Karpati G,
Holland P. The effect of glucocorticoids on the accumula-
tion of utrophin by cultured normal and dystrophic human
skeletal muscle satellite cells. Neuromuscular Disorders.
1995;5(2):105-14.
[31] Sklar RM, Brown Jr RH. Methylprednisolone increases
dystrophin levels by inhibiting myotube death during myo-
genesis of normal human muscle in vitro. Journal of the
Neurological Sciences. 1991;101(1):73-81.
[32] Takeuchi F, Yonemoto N, Nakamura H, Shimizu R, Komaki
H, Mori-Yoshimura M, et al. Prednisolone improves walk-
ing in Japanese Duchenne muscular dystrophy patients.
J Neurol. 2013;260(12):3023-9.
[33] Barber BJ, Andrews JG, Lu Z, West NA, Meaney FJ, Price
ET, et al. Oral Corticosteroids and Onset of Cardiomy-
opathy in Duchenne Muscular Dystrophy. The Journal of
Pediatrics. 2013;163(4):1080-4.e1.
[34] Smith AD, Koreska J, Moseley CF. Progression of scoliosis
in Duchenne muscular dystrophy. The Journal of Bone &
Joint Surgery. 1989;71(7):1066-74.
[35] Alman BA, Raza SN, Biggar WD. Steroid treatment and
the development of scoliosis in males with duchenne mus-
cular dystrophy. The Journal of Bone & Joint Surgery.
2004;86(3):519-24.
[36] Yilmaz ¨O, Karaduman A, Topalog˘lu H. Prednisolone ther-
apy in Duchenne muscular dystrophy prolongs ambulation
and prevents scoliosis. European Journal of Neurology.
2004;11(8):541-4.
[37] Townsend D, Yasuda S, Chamberlain J, Metzger JM. Car-
diac consequences to skeletal muscle-centric therapeutics
for duchenne muscular dystrophy. Trends in Cardiovascular
Medicine. 2009;19(2):49-54.
[38] van den Bergen JC, Hiller M, Bohringer S, Vijfhuizen L,
Ginjaar HB, Chaouch A, et al. Validation of genetic modi-
fiers for Duchenne muscular dystrophy: A multicentre study
assessing SPP1 and LTBP4 variants. Journal of Neurology,
Neurosurgery, and Psychiatry. 2015;86(10):1060-5.
[39] Flanigan KM, Ceco E, Lamar KM, Kaminoh Y, Dunn DM,
Mendell JR, et al. LTBP4 genotype predicts age of ambu-
latory loss in Duchenne muscular dystrophy. Annals of
Neurology. 2013;73(4):481-8.
[40] Pane M, Mazzone ES, Sormani MP, Messina S, Vita GL,
Fanelli L, et al. 6 Minute walk test in duchenne MD patients
with different mutations: 12 month changes. PLoS One.
2014;9(1):e83400.
[41] Findlay AR, Wein N, Kaminoh Y, Taylor LE, Dunn DM,
Mendell JR, et al. Clinical phenotypes as predictors of the
outcome of skipping around DMD exon 45. Annals of Neu-
rology. 2015;77(4):668-74.
